|
?:abstract
|
-
OBJECTIVE: Our aim was to evaluate the performance of two galactomannan assays (Platelia Aspergillus EIA, BioRadâ, and Aspergillus Galactomannan LFA, IMMYâ, Norman, OK, USA) in tracheal aspirate (TA) samples of consecutive critically ill patients with COVID-19. METHODS: We included critically ill patients, performed GM-EIA and GM-LFA in TA and followed them until development of CAPA or alternate diagnosis. CAPA was defined according to the modified AspICU criteria in patients with SARS-CoV-2 infection. We estimated sensitivity, specificity, positive and negative predictive values for GM-EIA, GM-LFA, the combination of both or either positive results for GM-EIA and GM-LFA. We explored accuracy using different breakpoints, through ROC analysis and Youden index to identify the optimal cutoffs. We described antifungal treatment and 30-day mortality. RESULTS: We identified 14/144 (9.7%) patients with CAPA, mean age was 50.35 (SD 11.9), the median time from admission to CAPA was eight days; 28.5% received tocilizumab and 30-day mortality was 57%. ROC analysis and Youden index identified 2.0 OD as the best cut-off, resulting in sensitivity and specificity of 57.1% and 81.5% for GM-EIA and 60% and 72.6% for GM-LFA, respectively. CONCLUSIONS: The diagnostic performance of galactomannan in tracheal aspirates improved after using a cutoff of 2 OD. Although BAL testing is the ideal test, centers with limited access to bronchoscopy may consider this approach to identify or rule out CAPA.
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}